NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCATS E-041-2021-3-EP-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same EP National Stage 24775449.2 Pending
NCI E-040-2012-0-EP-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen EP DIV 25206361.5 Pending
NCI E-264-2015-0-US-02 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE US CON 19/347,358 Pending
NCI E-054-2023-0-AU-01 T CELL RECEPTORS TARGETING Y220C OR R175H MUTATION IN P53 AU National Stage 2024241888 Pending
NCI E-136-2023-0-AU-01 1-THIOXO-2,4-DIHYDROTHIENO[2,3-E] [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN -5(1H)-ONE DERIVATIVES AS ALLOSTERIC INHIBITORS OF THE POLO-LIKE KINASE 1 (PLK1) POLO BOX DOMAIN (PBD) FOR THE TREATMENT OF CANCER AU National Stage 2024245755 Pending
NCI E-054-2023-0-JP-01 T CELL RECEPTORS TARGETING Y220C OR R175H MUTATION IN P53 JP National Stage 2025-556657 Pending
NCI E-054-2023-0-CA-01 T CELL RECEPTORS TARGETING Y220C OR R175H MUTATION IN P53 CA National Stage 3287225 Pending
NCI E-136-2023-0-CA-01 1-THIOXO-2,4-DIHYDROTHIENO[2,3-E] [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN
-5(1H)-ONE DERIVATIVES AS ALLOSTERIC INHIBITORS OF THE POLO-LIKE
KINASE 1 (PLK1) POLO BOX DOMAIN (PBD) FOR THE TREATMENT OF CANCER 		CA National Stage 3287290 Pending
NCI E-054-2023-0-US-02 T CELL RECEPTORS TARGETING Y220C OR R175H MUTATION IN P53 US National Stage 19/168,981 Pending
NCI E-136-2023-0-US-02 1-THIOXO-2,4-DIHYDROTHIENO[2,3-E] [1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-5(1H)-
ONE DERIVATIVES AS ALLOSTERIC INHIBITORS OF THE POLO-LIKE KINASE 1 (PLK1)
POLO BOX DOMAIN (PBD) FOR THE TREATMENT OF CANCER 		US National Stage 19/168,983 Pending
NICHD E-068-2023-0-PC-01 NON-PARAMETRIC DIFFUSION TENSOR DISTRIBUTION MAGNETIC RESONANCE IMAGING PCT PCT PCT/US2025/047646 Pending
NIAID E-080-2013-0-AU-11 Attenuation of Human Respiratory Syncytial Virus by Genome Scale Codon-Pair Deoptimization AU DIV 2025237901 Pending
NCI E-016-2018-0-KR-01 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS KR DIV 10-2025-7031862 Pending
NHLBI E-080-2023-0-US-02 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F]
FLUOROCELLOTRIOSE 		US National Stage 19/167,752 Pending
NCI E-029-2019-0-US-02 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION US DIV 19/334,152 Pending
NCI E-019-2026-0-PC-01 Identification of Inhibitors of the Catalytic RNA Subunit of RNase P PCT PCT PCT/US2025/047221 Pending
NHLBI E-080-2023-0-EP-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F]
FLUOROCELLOTRIOSE 		EP National Stage 24721311.9 Pending
NCI E-215-2024-0-PCT-01 COMPOUNDS FOR ACTIVATING MUCOSAL-ASSOCIATED INVARIANT T CELLS PCT PCT PCT/US2025/046881 Pending
NCATS E-041-2021-3-CN-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same CN National Stage 202480019785.9 Pending
NICHD E-198-2022-0-EP-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH EP National Stage 24717481.6 Pending
NCI E-266-2011-0-US-02 T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3 US DIV 19/331,502 Pending
NIDA E-053-2023-0-US-02 FLUORINATED MU-OPIOID RECEPTOR AGONISTS US National Stage 19/165,933 Pending
NCATS E-041-2021-3-JP-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same JP National Stage 2025-554186 Pending
NCATS E-041-2021-3-ZA-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same ZA National Stage 2025/07869 Pending
NCATS E-041-2021-3-CA-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same CA National Stage 3286087 Pending
NIAID E-182-2024-0-PC-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PCT PCT PCT/US2025/046419 Pending
NCATS E-041-2021-3-US-02 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same US National Stage 19/164,842 Pending
NEI E-131-2022-0-JP-01 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION JP National Stage 2025-553712 Pending
NIAID E-032-2019-0-AU-01 Nanoparticle-based Influenza Virus Vaccines and Uses Thereof AU DIV 2025230782 Pending
NIDA E-053-2023-0-CA-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS CA National Stage 3285739 Pending
NCATS E-112-2023-0-CN-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CN National Stage 202480018197.3 Pending
NCI E-231-2015-0-CN-01 Near Infrared Photoimmunotherapy (NIR-PIT) of Suppressor Cells CN DIV 202511279699.4 Pending
NIDA E-053-2023-0-AU-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS AU National Stage 2023437495 Pending
NIAID E-266-2023-0-US-01 Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation US National Stage 19/163,534 Pending
NEI E-131-2022-0-US-02 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION US National Stage 19/163,651 Pending
NIAID E-241-2014-0-EP-01 Recombinant Human/Bovine Parainfluenza Virus 3 (B/HPIV3) Expressing a Chimeric RSV/BPIV3 F Protein and Uses Thereof EP DIV 25201237.2 Pending
NCATS E-041-2021-3-AU-01 Combinations of Retinaldehyde Dehydrogenase 1 (RALDH1) Inhibitors and Immunostimulators and Methods Using Same AU National Stage 2024237910 Pending
NCI E-237-2017-2-EP-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 EP DIV 25200391.8 Pending
NCI E-040-2012-0-JP-02 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen JP DIV 2025-147544 Pending
NIEHS E-022-2023-0-AU-01 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF AU National Stage 2024224738 Pending
NICHD E-198-2022-0-US-02 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH US National Stage 19/162,323 Pending
NCI E-137-2024-0-PC-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PCT PCT PCT/US2025/044361 Pending
NCI E-137-2024-1-PC-01 VIRUS-LIKE PARTICLE CONJUGATES COMPRISING PHOTOACTIVATABLE DYE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PCT PCT PCT/US2025/044626 Pending
NEI E-131-2022-0-AU-01 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AU National Stage 2024240009 Pending
NCI E-183-2017-0-JP-03 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS JP DIV 2025-146568 Pending
NIAID E-216-2014-0-KR-01 RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES KR DIV 10-2025-7029082 Pending
NINDS E-070-2024-0-KR-01 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS KR National Stage 10-2025-7028974 Pending
NEI E-131-2022-0-CA-01 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION CA National Stage 3284565 Pending
NINDS E-070-2024-0-NZ-01 METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS NZ National Stage 824655 Pending
NINDS E-070-2024-0-AU-01 Methods of Diagnosing and Treating Multiple Sclerosis AU National Stage 2024214470 Pending